Top

Published in:

Open Access 01-12-2011 | Letter to the Editor

Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells

Authors: Mu Hao, Li Zhang, Gang An, Weiwei Sui, Zhen Yu, Dehui Zou, Yan Xu, Hong Chang, Lugui Qiu

Published in: Journal of Hematology & Oncology | Issue 1/2011

Abstract

The bone marrow microenvironment facilitates the survival, differentiation, and proliferation of myeloma (MM) cells. This study identified that microRNA-15a and -16 expressions tightly correlated with proliferation and drug sensitivity of MM cells. miRNA-15a/-16 expression in MM cells was significantly increased after treatment with cytotoxic agents. The interaction of bone marrow stromal cells (BMSC) with MM cells resulted in decreased miRNA-15a/-16 expression and promoted the survival of the MM cells. Interleukin-6 (IL-6) produced by BMSCs suppressed the expression of miRNA-15a and 16 in a time- and dose- dependent pattern, with the suppression on miRNA-15a being more significant than on miRNA-16. miRNA-15a-transfected MM cells were found to be arrested in G1/S checkpoint, and the transfected MM cells had decreased growth and survival. In conclusion, our data suggest that via suppressing miRNA-15a and -16 expressions, IL-6 secreted by BMSCs promotes drug-resistance in myeloma cells.

Available only for authorised users

Richardson PG, Barlogie B, Berenson J, Singhal S, Jagannath S, Irwin D, Rajkumar SV, Srkalovic G, Alsina M, Alexanian R, Siegel D, Orlowski RZ, Kuter D, Limentani SA, Lee S, Hideshima T, Esseltine DL, Kauffman M, Adams J, Schenkein DP, Anderson KC: A phase 2 study of bortezomib in relapsed, refractory myeloma. N Engl J Med. 2003, 348: 2609-2617. 10.1056/NEJMoa030288.CrossRefPubMed

Mitsiades CS, Mitsiades N, Munshi NC, Anderson KC: Focus on multiple myeloma. Cancer Cell. 2004, 6: 439-444. 10.1016/j.ccr.2004.10.020.CrossRefPubMed

Johann Micallef, Moyez Dharsee, Jian Chen, Suzanne Ackloo, Ken Evans, Luqui Qiu, Hong Chang: Applying mass spectrometry based proteomic technology to advance the understanding of multiple myeloma. Journal of Hematology & Oncology. 2010, 3: 13-10.1186/1756-8722-3-13.CrossRef

Jiahuai Tan, Shundong Cang, Yuehua Ma, Petrillo Richard, Delong Liu: Novel histone deacetylase inhibitors in clinical trials as anti-cancer agents. Journal of Hematology & Oncology. 2010, 3: 5-10.1186/1756-8722-3-5.CrossRef

Venumadhav Kotla, Swati Goel, Sangeeta Nischal, Christoph Heuck, Kumar Vivek, Bhaskar Das, Amit Verma: Mechanism of action of lenalidomide in hematological malignancies. Journal of Hematology & Oncology. 2009, 2: 36-10.1186/1756-8722-2-36.CrossRef

Raab Marc, Klaus Podar, Iris Breitkreutz: Multiple myeloma. Lancet. 2009, 374: 324-339. 10.1016/S0140-6736(09)60221-X.CrossRefPubMed

Hardin J, MacLeod S, Grigorieva I, Chang R, Barlogie B, Xiao H, Epstein J: Interleukin-6 prevents dexamethasone-induced myeloma cell death. Blood. 1994, 84: 3063-3070.PubMed

Mahindra A, Hideshima T, Anderson KC: Multiple myeloma: biology of the disease. Blood Rev. 2010, 24 (Suppl 1): S5-11.CrossRefPubMed

Anuradha Budhu, Junfang Ji, Wang Xin: The clinical potential of microRNAs. Journal of Hematology & Oncology. 2010, 3: 37-10.1186/1756-8722-3-37.CrossRef

10.

Roccaro AM, Sacco A, Thompson B, Leleu X, Azab AK, Azab F, Runnels J, Jia X, Ngo HT, Melhem MR, Lin CP, Ribatti D, Rollins BJ, Witzig TE, Anderson KC, Ghobrial IM: MicroRNAs 15a and 16 regulate tumor proliferation in multiple myeloma. Blood. 2009, 113: 6669-6680. 10.1182/blood-2009-01-198408.PubMedCentralCrossRefPubMed

11.

Fonseca R, Blood E, Rue M, Harrington D, Oken MM, Kyle RA, Dewald GW, Van Ness B, Van Wier SA, Henderson KJ, Bailey RJ, Greipp PR: Clinical and biologic implications of recurrent genomic aberrations in myeloma. Blood. 2003, 101: 4569-4575. 10.1182/blood-2002-10-3017.CrossRefPubMed

12.

Lee SO, Masyuk T, Splinter P, Banales JM, Masyuk A, Stroope A, Larusso N: microRNA15a modulates expression of the cell-cycle regulator Cdc25A and affects hepatic cystogenesis in a rat model of polycystic kidney disease. J Clin Invest. 2008, 118: 3714-3724. 10.1172/JCI34922.PubMedCentralCrossRefPubMed

Title: Suppressing miRNA-15a/-16 expression by interleukin-6 enhances drug-resistance in myeloma cells
Authors: Mu Hao
Li Zhang
Gang An
Weiwei Sui
Zhen Yu
Dehui Zou
Yan Xu
Hong Chang
Lugui Qiu
Publication date: 01-12-2011
Publisher: BioMed Central
Published in: Journal of Hematology & Oncology / Issue 1/2011
Electronic ISSN: 1756-8722
DOI: https://doi.org/10.1186/1756-8722-4-37

Webinar | 19-02-2024 | 17:30 (CET)

Keynote webinar | Spotlight on antibody–drug conjugates in cancer

Watch now

Antibody–drug conjugates (ADCs) are novel agents that have shown promise across multiple tumor types. Explore the current landscape of ADCs in breast and lung cancer with our experts, and gain insights into the mechanism of action, key clinical trials data, existing challenges, and future directions.

Dr. Véronique Diéras

Prof. Fabrice Barlesi

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2011

A meta-analysis of CAG (cytarabine, aclarubicin, G-CSF) regimen for the treatment of 1029 patients with acute myeloid leukemia and myelodysplastic syndrome

Frequency analysis of TRBV subfamily sjTRECs to characterize T-cell reconstitution in acute leukemia patients after allogeneic hematopoietic stem cell transplantation

Dasatinib preferentially induces apoptosis by inhibiting Lyn kinase in nilotinib-resistant chronic myeloid leukemia cell line

Unfolded protein response in cancer: the Physician's perspective

A single-tube allele specific-polymerase chain reaction to detect T315I resistant mutation in chronic myeloid leukemia patients

Enhanced self-renewal of hematopoietic stem/progenitor cells mediated by the stem cell gene Sall4

Keynote webinar | Spotlight on antibody–drug conjugates in cancer